


THE LANCET

Infectious Diseases


Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Arora RK, Joseph A, Wyk JV, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. *Lancet Infect Dis* 2020; published online August 4. [https://doi.org/10.1016/S1473-3099\(20\)30631-9](https://doi.org/10.1016/S1473-3099(20)30631-9).



a.



b.

Figure: Distribution of SARS-CoV-2 serosurveys across countries; national and regional seroprevalence estimates vs case counts. (A) The number of SARS-CoV-2 serosurveillance studies in each country that have reported results and are being monitored by SeroTracker. Studies stratified by scope: national (country-wide), regional (e.g., state or province), and local (municipal). (B) Seroprevalence and cumulative incidence of confirmed COVID-19 cases. National and regional seroprevalence estimates of the general population and blood donors were aggregated, with 95% confidence intervals shown. Seroprevalence estimates from March 1 to July 23, 2020 were included. Cumulative case counts are as of July 23, 2020.